TESARO (TSRO) to Expand Development Program for Niraparib Focused on the Treatment of Front-Line Metastatic Ovarian and Lung Cancers and Metastatic Breast Cance
Tweet Send to a Friend
TESARO, Inc. (NASDAQ: TSRO) today announced a substantial expansion of its niraparib clinical development program. Following the landmark results of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE